Bleeding Risk Diagnostic Test
Assessment of bleeding and clotting risk in emergency/trauma settings
Key Facts
About FloBio
FloBio is developing a first-of-its-kind, fluidic-based point-of-care diagnostic platform to transform the management of bleeding and clotting disorders. Its core technology simulates in-vivo clot formation under flow, providing a multiplex, functional assessment of platelet and fibrin activity in whole blood within 10-15 minutes. The company's initial focus is on detecting and quantifying Direct Oral Anticoagulants (DOACs) to guide reversal strategies, addressing a critical unmet need in emergency medicine. With FDA Breakthrough Device Designation for its bleeding risk test, FloBio is positioned to enter a significant market driven by the growing safety concerns and costs associated with blood thinners.
View full company profile